Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Refer Your Friends & Family to Participate

    Simply help us get the word out about Prism Clinical Research and we’ll give you $100 for every friend you refer that completes a study.

    It’s that easy! Make money with each referral, and there’s no limit to how many friends you can refer!

    Rules:

    • Subject must complete the study.
    • Subject may not be referred more than one time.
    • Subjects may not refer each other.
    • Subject must complete the study before payment can be received.
    • Subjects eligible for Referral: (1) Must not be in Prism Clinical Research database; (2) Must not have participated in any study at Prism.
    • In the event that a subject is referred by multiple people, the first person who referred will receive payment.
    • Eligibility will be determined by Prism. Prism reserves the right to revise or eliminate this program at any time without notice.

     

     

  • Diagnosed with Liver Impairment?

    Prism Research has upcoming studies for individuals diagnosed with liver impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     

    If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

    The current study we have available is Study 1702!

  • Study 1620: Male and Female Participants with Nasal Polyps

    Research Purpose: Study 1620 is designed to determine the safety and tolerability of an investigational drug being developed for the treatment of Chronic Rhinosinusitis with Nasal Polyps.

    *Must be diagnosed with Nasal Polyps to participate in this study*


    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women may participate if they meet one of the following criteria: postmenopausal, hysterectomy and/or bilateral oophorectomy, medically confirmed ovarian failure, tubal ligation or bilateral salpingectomy.

    Age

    18-65 years

    Body Mass Index (BMI)

    Between 17.5 – 35.0 kg/m²

    Tobacco/Nicotine Use

    Must be willing to abstain from tobacco and/or nicotine containing products for 24 hours prior to dosing and during the clinic stay.

    Health History

    Must be healthy; with the exception of diagnosed nasal polyps and chronic rhinosinusitis.

    Restricted Medications

    All medications will be reviewed for inclusion prior to screening.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 12 months.

    Clinic Stay

    • Participants will admit to Prism Clinical Research one-time for 2 overnights

    Clinic Visits

    • There are up to 13 follow-up clinical visits

     

    Compensation for participation time:   Up to $1,860                           


    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1702: Participants with Reduced Liver Function

    Research Purpose: Study 1702 is designed to evaluate bacteria in the digestive system and different methods of stool sample collection. No investigational drug will be administered. Participants will collect 8 stool samples from 4 different bowel movements over the course of 10 days. 

     Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate

    Age

    18-75 years

     

    Study Time Commitment: Study participation will last for approximately 10 days.

    Outpatient Visits

    • There are a total of 3 outpatient visits including screen

     

    Compensation for participation time:   Up to $410.00                     

    For information regarding this study contact Dayna at 651-724-5047 or email daynas@prismresearchinc.com

  • Study 1703:Healthy Participants Who Have Experienced episodes of cold sores due to Herpes Simplex Virus Type 1 infection

    Research Purpose: Study 1703 is a study to evaluate immune response in subjects infected with Herpes Simplex Virus Type 1 (HSV-1).

     *Must have experienced episodes of cold sores due to HSV-1 *

    For information regarding this study contact Lindsay: 651-362-3360 or lindsayd@prismresearchinc.com

     Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant or breastfeeding are allowed to participate.  Women of childbearing potential must agree to use approved birth control while in the study and for a period of one month after study completion.

    Age

    18-64 years

    Body Mass Index (BMI)

    Between 18-35 kg/m²

    Tobacco/Nicotine Use

    Nicotine use is permitted

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    Therapy with glucocorticoid or immunosuppressants 4 weeks prior to screening or anti-viral therapy any time in the past 12 months

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 12 weeks.

    In-clinic Stay

    • There are no in-clinic stays required for this study

    Out-clinic Visits Group A

    • There is one screening visit and 3 visits at the clinic

    Out-clinic Visits Groups B and C

    • There is one screening visit and one visit at the clinic

    Compensation for participation time:   Group A up to $340.00; Groups B & C up to $170.00

                           

    For information regarding this study contact Lindsay: 651-368-3360 or lindsayd@prismresearchinc.com

     

Recent News

  • New Clinical Research Consortium Provides Integrated Development Platform in Medical Alley

    Prism Research is one of 5 leading Minnesota based research organizations that have partnered to provide the most comprehensive clinical development platform in the industry. To find out more, click the link below.

    http://bit.ly/2p040od

  • 7- Signs of Liver Problems

    Prism is now conducting studies for volunteers with liver impairment. Quick- read- article to address 7 signs of a bad liver condition. 

    http://bit.ly/2qvYpnr

     

  • DaVita Clinical Research and Prism Clinical Research choose Verified Clinical Trials to prevent duplicate enrollment in clinical trials

    MINNEAPOLIS (Jan. 17, 2017) – DaVita Clinical Research (DCR), a specialty contract research organization with services spanning the full spectrum of drug and device development, and Prism Clinical Research, a leader in providing fully integrated clinical research services to pharma/device companies and clinicians, today announced Verified Clinical Trials (VCT) has been selected by both companies as an exclusive provider to further prevent duplicate enrollment in clinical trials. 

     

    Simultaneously enrolling in multiple clinical trials, or duplicate enrollment, has become a serious problem in the clinical research world. A growing number of research volunteers attempt to jump from one study to another without waiting for the appropriate amount of time to lapse. This creates dangerous issues for the drug manufacturer, the research site, the data quality, and, most importantly, the volunteer.

     

    “We are pleased to have these two clinical research leaders join out network,” said Dr. Mitchell Efros, CEO of VCT. “Our system will allow both companies to take big steps forward in preventing duplicate enrollment and the risks associated.”

     

    VCT maintains a global clinical trial research subject database registry to counter attempts at duplicate enrollment in clinical trial research. The majority of phase I units and an increasingly large number of late phase sites in North America use Verified Clinical Trials, making VCT by far the largest North American clinical research subject database registry in both early and late phase clinical trials.

     

    “DCR is passionate about ensuring data quality and research subject safety,” said Amy Young, vice president and general manager of DCR. “Partnering with Prism and using the VCT system is the right thing to do for all our stakeholders.”

     

    Experts and leaders in the field of hepato-renal clinical trials, Prism and DCR join a vast network of research sites and pharmaceutical companies in their efforts to prevent duplicate enrollment and other important protocol violations in clinical trials.

     

    ”Prism is glad to be participating in this joint effort with our research neighbor, DCR,” said Jeff Cosgrove, president of Prism Research. “We’ve always been proactive in combating dual enrollment, but VCT gives us state-of-the-art technology and processes toward that end.”

     

    Located in close proximity to the Minneapolis and St. Paul metropolitan area, Prism and DCR specialize in early phase clinical research in healthy volunteer trials and many patient-based volunteer trials, including those in hepatic and renal insufficiency populations.

     

     

    About Prism Clinical Research

    Prism Clinical Research is a Twin Cities–based clinical research company committed to the advancement of improved medical knowledge and the community’s health. Since 2005, Prism has provided FDA-approved, investigational pharmaceutical and medical device testing services on behalf of drug and device manufacturers, academic and private physicians, as well as other researchers across Minnesota.

     

    About DaVita Clinical Research

    DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment and completion of retrospective, prospective and pragmatic clinical trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 175 client companies. DCR’s Early Clinical Research unit (Phase I-IIa) and Late Phase Clinical Research (Phase IIb through post-marketing) network of physicians and investigative sites, and Real World Healthcare Data are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit http://www.davitaclinicalresearch.com.

     

    About Verified Clinical Trials

    Verified Clinical Trials is a forward thinking company developed by experts active in the clinical research community to proactively improve research subject safety and data quality in clinical research trials. Verified Clinical Trials halts duplicate enrollment in clinical trials and defines itself as the world’s leader in the field of database registries in clinical trial research. Verified Clinical Trials is the only clinical research database registry designed specifically to enhance the quality of both early and late phase trials, and has the scalability to reach all sites nationally as well as on a global level. Verified Clinical Trials offers numerous other value-added services to the clinical research site, CRO, and Pharmaceutical Sponsor that prove invaluable with regards to financial and legal issues and liabilities. Verified Clinical Trials prevents several other key protocol deviations. For more information, RSVP to or visit

    http://www.verifiedclinicaltrials.com.

  • BMI 101: What's in a number?

    BMI stands for "Body Mass Index," and it's a calculation determined by your heigh and weight. There is almost always a BMI range in Prism's studies. And, let's be honest, for many of us that range can be a tight fit.

    Why does the BMI range exist? To provide an expected norm within which the population of participants will fall.

    Why is there a BMI limit? A participant with a higher BMI may require a greater dose of the study drug and therefore may metabolize the drug differently than a person with a lower BMI.

    Why does the BMI range change from study to study? The range is determined by the study sponsor - the company paying Prism Research to conduct the study. The range is based on the type of study, the procedures being done, and the study drug.

  • Prism Rides "Tour de Cure"

    Tour de Cure

    Prism staff took part in the American Diabetes Association's "Tour de Cure" June 1st. Our ride wasn't the end of our organization's efforts to stop diabetes. We're advancing diabetes research right here in St. Paul!

    If you or a loved one suffers from diabetes, consider telling them about Prism's continued commitment to offer studies for diabetics.

  • OmniComm Systems, Inc. Celebrates Innovation and Excellence at Third Annual Innovation Forum

    Prism Research receives Innvovation and Excellence Award! http://www.omnicomm.com/press/2013_11_22__OmniComm_Systems_Celebrates_Innovation_and_Excellence_at_Third_Annual_Innovation_Forum.html

  • Our Hometown -The Twin Cities

    We love being a part of the Twin Cities metro for so many reasons.  Great food, great lakes, but most importantly great volunteers and people.  Below is a link to why hometown foodie Andrew Zimmern loves the Twin Cities!

    http://andrewzimmern.com/2013/08/27/my-hometown/?sf17040496=1

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel